Hemp seed protein hydrolysates and its bioactive peptides mitigate muscle atrophy in in vitro and in vivo models

Hemp is increasingly being studied not just as a source of plant protein, but as a source of biologically active compounds that may influence muscle health. In this new study, researchers found that hemp seed protein hydrolysates helped protect against muscle atrophy in both cell and animal models, improving grip strength and muscle mass while also influencing pathways involved in protein synthesis, degradation, inflammation, and apoptosis.

The researchers also identified three bioactive peptides—AERGF, VL, and GLK—that showed particularly strong anti-atrophy effects, with evidence pointing to AMPK/FoxO3a signaling as an important part of their activity. Notably, the hemp protein hydrolysates produced stronger effects than whey protein in the mouse model, highlighting hemp seed as a potentially valuable source of functional proteins and bioactive peptides for future muscle-health research.

“We recently demonstrated that hemp seed protein hydrolysates (HPH), produced through enzymatic hydrolysis, protect against muscle atrophy in both in vitro and in vivo models.

This study aimed to optimize the HPH production method and elucidate its mechanism of action in preventing muscle atrophy, including the identification of bioactive peptides within HPH.

To optimize HPH production, we compared the degree of protein hydrolysis using alcalase and flavourzyme, both individually and in combination. Ultimately, we produced HPH by treating it with 2% flavourzyme for 2 h.

Our results showed that HPH increased cell viability and normalized reactive oxygen species levels in H2O2-treated C2C12 myoblasts. In a mouse model of muscle atrophy induced by dexamethasone (DEX), HPH improved grip strength and increased muscle mass, demonstrating effects stronger than those of whey protein. Immunoblotting analysis indicated that HPH activates protein synthesis pathways while inhibiting protein degradation, apoptosis, and the production of inflammatory cytokines in skeletal muscle. Additionally, we analyzed the peptide composition of HPH and investigated the anti-atrophic effects of specific peptides in C2C12 myotubes.

Among fourteen peptide candidates, peptides AERGF, VL, and GLK showed the most significant effects on enhancing myotube diameter and reducing the expression of ubiquitin ligases and cleaved PARP in DEX-treated C2C12 myotubes. These peptides also increased the phosphorylation of AMPK and FoxO3a, which were reduced by DEX. Notably, their protective effects against myotube atrophy diminished when the cells were co-treated with an AMPK inhibitor.

These findings demonstrate that HPH and its bioactive peptides effectively mitigate DEX-induced muscle atrophy by positively regulating muscle protein synthesis and degradation pathways.”

https://pubmed.ncbi.nlm.nih.gov/42680322

https://www.sciencedirect.com/science/article/abs/pii/S0963996926017126?via%3Dihub

Transient CB2R modulation durably restricts breast cancer plasticity by stabilizing a luminal like cell identity

New breast cancer research suggests that brief modulation of cannabinoid receptor 2 (CB2R), including with THC, may have lasting effects on tumor cell behavior. Researchers found reduced self-renewal, invasiveness, and tumor-initiating capacity, along with greater tamoxifen sensitivity and a durable shift toward a more stable luminal-like cell identity.

“Cancer cell plasticity enables therapy resistance and metastasis by allowing transitions between stem-like and differentiated states. Differentiation-based strategies aim to stabilize tumor cell identity, yet pharmacological approaches that induce durable lineage restriction remain limited.

Here, we show that transient modulation of cannabinoid receptor 2 (CB2R) durably restricts breast cancer cell plasticity by stabilizing a luminal-like cell state. Using patient-derived and murine tumor organoids, we demonstrate that brief, low-dose CB2R modulation reduces self-renewal, invasiveness and tumor-initiating capacity, while enhancing tamoxifen sensitivity and limiting the emergence of resistant phenotypes.

These effects persist under pro-dedifferentiation conditions, including TGFβ exposure, stromal co-culture, immune signaling and mechanical stress, and are maintained in vivo following orthotopic transplantation. RNA sequencing reveals a progressive transition from an early plastic state toward a stabilized luminal-like identity, supported by CUT&Tag profiling that uncovers chromatin remodeling associated with this stabilization.

Together, our findings redefine CB2R as a regulator of tumor cell state and establish transient CB2R modulation as a strategy to durably constrain breast cancer plasticity through differentiation-based therapy.”

https://www.nature.com/articles/s42003-026-10837-1

“Low-dose THC keeps breast cancer cells in tumor models from reverting to an aggressive state”

https://medicalxpress.com/news/2026-09-dose-thc-breast-cancer-cells.html

Trimetallic MgO-ZnO-BaO Nanoparticles Catalyzed Biodiesel Production Using Industrially Cultivated Cannabis sativa L. Oil: RSM Optimization and Assessment of Fuel Properties

Industrial hemp continues to demonstrate value far beyond traditional agricultural uses. In this study, researchers combined hemp seed oil with a trimetallic nanoparticle catalyst and process optimization technology to produce biodiesel at a 92% yield, with fuel characteristics comparable to established ASTM standards—highlighting Cannabis sativa as a potential renewable feedstock for advanced biofuel production.

“Biodiesel synthesis by utilizing nonedible species of oil-bearing seeds is a viable, eco-friendly, and pragmatic approach to combating fossil fuel shortages and environmental pollution.

Therefore, in the present research work, hemp oil was extracted in good yield (29.9%) utilizing industrial hemp ( Cannabis sativa L.) seeds cultivated in a greenhouse at PCSIR-Lahore, Pakistan, using hydroponic technology (Crop 2022).

For maximum biodiesel production, a ternary metal (MgO-ZnO-BaO NPs) nanocatalyst was designed and thoroughly characterized by PXRD, SEM, EDX, and FTIR analysis. Afterward, the nanocatalyst-assisted transesterification of hemp oil was carried out. The transesterification reaction of hemp oil was optimized by response surface methodology based on central composite design (CCD-RSM). A quadratic polynomial equation was employed to predict the optimal yields, while analysis of variance (ANOVA) identified the statistically significant factors influencing the process.

The maximum yield of biodiesel (92%) was obtained by adjusting the methanol to hemp oil molar ratio (6:1), temperature at 65°C, MgO-ZnO-BaO NPs dosage of 2.5 g, and a reaction time of 3 h with a constant stirring rate of 750 rpm. The hemp-oil-based biodiesel was characterized by FTIR and GC-MS analysis. Fuel characteristics of biodiesel were determined according to ASTM D 6751, which were comparable to literature and ASTM standards.

The findings of this comprehensive study proved the credibility of hemp seed oil as a feasible nonfood, nonconventional feedstock for producing high-quality biodiesel.”

https://pubmed.ncbi.nlm.nih.gov/40739776

https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jemt.70051

Benefits of cannabis in treating lower urinary tract symptoms: A scoping review

Cannabis-based therapies may offer another approach to managing lower urinary tract symptoms such as urinary urgency, frequency, and incontinence. A 2026 scoping review found encouraging evidence that THC, CBD, and combined cannabinoid formulations can improve several urinary symptoms and quality-of-life measures, with the most consistent evidence found among patients with multiple sclerosis.

Introduction: Anticholinergics and β3-agonists remain the mainstay for bladder dysfunction but are limited by side effects and poor adherence. Cannabinoids are a potential alternative given receptor distribution in bladder control pathways. Early studies suggested that cannabis may demonstrate benefits in overactive bladder (OAB) and lower urinary tract symptoms (LUTS), but findings are limited by small sample sizes and cross-sectionality. This review investigates the therapeutic utility of cannabis and its impact on LUTS.

Methods: This scoping review was conducted following Cochrane and PRISMA guidelines. Eligible studies included adults with OAB symptoms due to neurogenic disease, benign prostatic hyperplasia (BPH), or cystitis, treated with cannabis vs. placebo, no treatment, or active therapies. Outcomes included urinary function and quality of life. Databases searched included MEDLINE, EMBASE, and CENTRAL. Non-English studies were excluded.

Results: From 998 abstracts, 31 full-text articles were reviewed and 12 were included. Studies showed consistent evidence on the effectiveness of cannabis-based therapies for managing LUTS, particularly in patients with multiple sclerosis (MS). Cannabis interventions, including THC, CBD, and combined formulations, showed some improvements in incontinence episodes, frequency, and quality-of-life measures. Mild adverse effects, including dizziness and dry mouth, were common (2-18%) and sometimes led to treatment discontinuation. Nine of 12 studies were done on MS populations, and only three studies were randomized controlled trials.

Conclusions: Evidence for the benefits of cannabis in treating LUTS is limited and largely observational. While preliminary findings are encouraging, randomized trials focusing on patient-centered outcomes are needed to clarify its role in clinical practice.”

https://pubmed.ncbi.nlm.nih.gov/42678682

https://cuaj.ca/index.php/journal/article/view/9478

Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain

In a study of 183 adults using edible cannabis for chronic low back pain, researchers found no significant acute changes in executive function, episodic memory, or processing speed after cannabis use. Participants using CBD-dominant products performed better on working memory than those using CBD + THC one hour after use, while the CBD group also showed more stable verbal-learning scores than participants using THC or mixed CBD/THC products. The findings add useful evidence to the discussion of how different cannabinoid profiles may affect cognition when cannabis is used for chronic pain.

Rationale: An estimated two-thirds of medical cannabis users in the United States are motivated by chronic pain, but clinical guidance remains guarded as to whether the potential benefit of cannabinoids for pain outweighs potential risks, such as effects on cognition.

Objectives: In a study where participants experienced benefits of cannabinoids for pain and tension, we evaluated cannabis effects on executive function, processing speed, memory, and verbal learning following acute use for chronic, non-specific low back pain.

Methods: Participants were in one of three self-selected edible cannabis groups: a) CBD-dominant, b) THC-dominant, or c) a mixed ratio of CBD to THC and completed a battery of cognitive tasks at pre-use, 1 h post-use use, and 2 h post-use.

Results: Among 183 participants (56.8% female; Mage = 45.6), those in the group using CBD outperformed participants using CBD + THC 1 h post use in working memory and produced more stable scores in verbal learning after use than participants using THC or CBD + THC. Additionally, while older age was associated with better working memory in the CBD group before use, that relationship was progressively attenuated over the subsequent timepoints. There were no significant effects of cannabis use on cognition in the domains of executive function, episodic memory, or processing speed.

Conclusions: Given the ubiquity of cannabis use for chronic pain and the ongoing call for more data, this study is relevant for informing clinical guidance on whether, and how, cannabis could be used in this context. In particular, understanding the acute impact on cognition from cannabis is critical, as cognitive functioning directly affects patients’ daily lives and quality of life.”

https://pubmed.ncbi.nlm.nih.gov/42678518

“In summary, these findings support CBD’s potential to preserve cognitive performance in the context of chronic pain, contrasting with the more variable effects of THC across cognitive domains. The observed influence of age, particularly among those using CBD, suggests that both cannabinoid composition and individual factors shape cognitive outcomes following acute cannabinoid use.”

https://link.springer.com/article/10.1007/s00213-026-07157-x

Cannabidiolic acid causes a defect in tail retraction of migrating MDA-MB-231 cells: possible involvements of Rho-associated protein kinases inhibition and accumulation of vinculin at the rear of migrating cells

A new study adds mechanistic detail to earlier evidence that cannabidiolic acid (CBDA) can interfere with the migration of highly aggressive MDA-MB-231 breast cancer cells. Researchers found that CBDA inhibited Rho-associated kinases (ROCKs), impaired tail retraction, altered cell shape and caused vinculin to accumulate at the trailing edge—revealing another way this cannabis-derived compound may disrupt cellular behavior involved in cancer spread.

“We previously reported that cannabidiolic acid (CBDA), a major cannabinoid constituent of the fiber-type cannabis plant, abrogates the migration of highly aggressive human breast cancer MDA-MB-231 cells and activates the small GTPase RhoA by inhibiting protein kinase A. However, the mechanism(s) mediating RhoA signaling, which decreases cell migration, have not yet been comprehensively elucidated.

RhoA is an upstream mediator of Rho-associated kinases (ROCKs), diaphanous-related formins (DIAPHs), the RhoA-ROCK pathway (tail retraction) and the RhoA-DIAPH pathway (lamellipodia formation).

Herein, we identified CBDA as an inhibitor of ROCKs (at approximately 25 μM), which markedly elongated the cell body of MDA-MB-231 cells, similar to Y-27632, an established ROCK inhibitor.

CBDA stimulated lamellipodia formation at the leading edge, whereas NSC23766 (an established Rac1 inhibitor) completely blocked this elongated morphology. Biochemical analyses, including time-lapse imaging and confocal laser scanning microscopy, revealed that, compared to Y-27632, CBDA can induce impaired tail retraction coupled with unidirectional elongation of the cell body, upregulate the mRNA expression of DIAPHs and accumulate vinculin, an adhesion protein, at the trailing edge without affecting its expression.

These results indicate the potential of CBDA as a new candidate for the synthesis of ROCK inhibitors, which can evoke the directed elongation of MDA-MB-231 cells.”

https://pubmed.ncbi.nlm.nih.gov/42186359

https://academic.oup.com/jb/article-abstract/180/2/143/8693860?redirectedFrom=fulltext